MENU
+Compare
VRCA
Stock ticker: NASDAQ
AS OF
Jun 13 closing price
Price
$0.62
Change
-$0.05 (-7.46%)
Capitalization
57.63M

VRCA Verrica Pharmaceuticals Forecast, Technical & Fundamental Analysis

Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases... Show more

VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for VRCA with price predictions
Jun 13, 2025

VRCA's MACD Histogram crosses above signal line

The Moving Average Convergence Divergence (MACD) for VRCA turned positive on June 09, 2025. Looking at past instances where VRCA's MACD turned positive, the stock continued to rise in of 46 cases over the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on June 09, 2025. You may want to consider a long position or call options on VRCA as a result. In of 88 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

VRCA moved above its 50-day moving average on June 02, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for VRCA crossed bullishly above the 50-day moving average on May 19, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 14 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where VRCA advanced for three days, in of 274 cases, the price rose further within the following month. The odds of a continued upward trend are .

Bearish Trend Analysis

The 10-day RSI Indicator for VRCA moved out of overbought territory on May 21, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 19 similar instances where the indicator moved out of overbought territory. In of the 19 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRCA declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

VRCA broke above its upper Bollinger Band on June 12, 2025. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for VRCA entered a downward trend on May 14, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. VRCA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: VRCA's P/B Ratio (149.254) is slightly higher than the industry average of (16.972). P/E Ratio (0.000) is within average values for comparable stocks, (59.618). VRCA's Projected Growth (PEG Ratio) (0.000) is slightly lower than the industry average of (2.336). Dividend Yield (0.000) settles around the average of (0.040) among similar stocks. P/S Ratio (5.999) is also within normal values, averaging (257.692).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRCA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
VRCA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

VRCA is expected to report earnings to rise 45.00% to -11 cents per share on August 12

Verrica Pharmaceuticals VRCA Stock Earnings Reports
Q2'25
Est.
$-0.12
Q1'25
Beat
by $0.03
Q4'24
Beat
by $0.06
Q3'24
Missed
by $0.05
Q2'24
Beat
by $0.04
The last earnings report on May 13 showed earnings per share of -7 cents, beating the estimate of -10 cents. With 128.84K shares outstanding, the current market capitalization sits at 57.63M.
A.I. Advisor
published General Information

General Information

a manufacturer of pharmaceutical products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Pharmaceuticals Major
Address
44 West Gay Street
Phone
+1 484 453-3300
Employees
100
Web
https://www.verrica.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
REI0.870.02
+2.88%
Ring Energy
DNOW15.070.03
+0.20%
DNOW
VTMX27.80-0.20
-0.71%
Corporacion Inmobiliaria Vesta SAB de CV
PMVP1.08-0.01
-0.92%
PMV Pharmaceuticals
ANET92.35-3.42
-3.57%
Arista Networks Inc

VRCA and Stocks

Correlation & Price change

A.I.dvisor tells us that VRCA and PBYI have been poorly correlated (+32% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that VRCA and PBYI's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRCA
1D Price
Change %
VRCA100%
-7.52%
PBYI - VRCA
32%
Poorly correlated
-5.90%
ACOG - VRCA
30%
Poorly correlated
-2.65%
SLNO - VRCA
29%
Poorly correlated
-1.31%
FGEN - VRCA
29%
Poorly correlated
-14.46%
QURE - VRCA
27%
Poorly correlated
-4.07%
More